TrialBlood advances2023
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Hua-Jay J Cherng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papertrialcites it
TrialBlood advances2023
Hua-Jay J Cherng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.